Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era

Conclusion.Although nearly half of new patients referred to a phase I clinic had prior molecular profiling, the proportion subsequently enrolled into clinical trials was low. Prior molecular profiling was not an independent predictor of clinical trial enrollment.Implications for Practice.The landscape of oncology drug development is evolving alongside technological advancements. Recently, large academic medical centers have implemented clinical sequencing protocols to identify patients with actionable genomic alterations to enroll in therapeutic clinical trials. This study evaluates patient referral and enrollment patterns in a large academic phase I clinical trials program following the implementation of a molecular profiling program. Performance status and referral from a physician within the institution were associated with successful trial enrollment, whereas prior molecular profiling was not an independent predictor.

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Tira Tan, Michael Rheaume, Lisa Wang, Helen Chow, Anna Spreafico, Aaron R. Hansen, Albiruni R.A. Razak, Lillian L. Siu, Philippe L. Bedard Tags: New Drug Development and Clinical Pharmacology, Precision Medicine Clinic: Molecular Tumor Board, Health Outcomes and Economics of Cancer Care, Cancer Diagnostics and Molecular Pathology Source Type: research